1. Medtech Insight
  2. >>Policy & Regulation

Device User-Fee Agreement Gets A Senate Hearing

 
• By Sue Darcey

US FDA user-fee reauthorization agreements, including the medical device MDUFA IV package, will be dissected at a Senate Health, Education, Labor, and Pensions (HELP) Committee hearing on March 21.

The device user-fee reauthorization agreement inked by US FDA and industry groups last summer will finally get a public hearing in Congress: March 21 in the Senate Help, Education, Labor and Pensions Committee.

In addition to devices, the hearing will address user-fee agreements for drugs and biologics. FDA's current user-fee programs are scheduled to expire Sept. 30. Congress needs to approve the reauthorization...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.